We’re crossing the English channel this week to visit Paris. There, in the very center of the city, Hybrigenics is making impressive advances in the development of inecalcitol, a new drug for leukemia and prostate cancer.
Mission: Hybrigenics develops therapies for proliferative diseases, its main focus being cancer. The company’s lead candidate, inecalcitol, is a vitamin D receptor agonist currently being evaluated in 4 Phase II clinical trials for prostate cancer and myeloid leukemia. In addition, the company is exploring deubiquitinating enzymes (DUBs), which play a key role in regulating cell proliferation and can induce cancer when they mutate.
Comment: Hybrigenics just announced preliminary data from a Phase II trial for chronic myeloid leukemia. Its progress in 4 parallel clinical trials without a licensing partner is pretty impressive. Instead, the biotech gets revenues from its subsidiary Hybrigenics Services, specialized in the study of protein interactions. For DUBs, still in the drug discovery phase, the company does have the support of a big partner, the French pharma Servier.
We visited Hybrigenics during the Labiotech Tour in France:
Images from Zabotnova Inna /Shutterstock, Labiotech Map